Popular Articles
Teeth Whitening

Parkinson's Disease As A Risk Factor For Compulsive Gambling And Impulse Control Disorders
There is also increasing knowledge about higher frequency of compulsive behavior in patients with PD compared to the general population. "These impulse control disorders such as pathological gambling, hyper-sexuality, compulsive shopping, compulsive eating or compulsive overuse of dopaminergic drugs can lead to monetary losses or worsen social handicap of PD patients," Professor Bassetti explains.
generic viagra online
NeurogesX Announces New PDUFA Date For Qutenza(TM) New Drug Application
NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date from August 16, 2009 to November 16, 2009 to review the new drug application (NDA) for Qutenza(TM) to manage pain associated with postherpetic neuralgia (PHN).
plastic surgery before after
News of the day
Celgene Announces Positive Top Line Data From Randomized Controlled Phase II Study Of Apremilast In Psoriatic Arthritis
Celgene Corporation (NASDAQ: CELG) announced the preliminary results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast - a novel, orally available small molecule that exhibits anti- inflammatory activities through the suppression of multiple pro-inflammatory mediators and cytokines - in adult patients with psoriatic arthritis (CC-10004-PSA-001). The study met its primary objective of assessment of ACR20 at 12 weeks. ACR20 is defined as the percentage of patients achieving a 20% or better improvement according to the American College of Rheumatology (ACR) criteria. ACR20 is the primary assessment utilized by the U.S. Food and Drug Administration for assessment of efficacy in psoriatic arthritis, as well as rheumatoid arthritis.
Public Health

The End Of The Line For Existing Stem Cell Research?

Time is short for scientists to respond to the call for comments on the National Institutes of Health (NIH) proposed guidelines for the use of human embryonic stem (ES) cell lines and their eligibility for federal funds. On May 26, the window to provide feedback will close, and the drafted rules leave the possibility that funding for almost all existing cell lines will disappear. In a Forum article published online on May 14 by Cell Press in the journal Cell Stem Cell, Patrick Taylor, deputy general counsel at Children"s Hospital Boston, explains some of the legal implications of the NIH"s new funding rules, should they be adopted as written. Since the rules are retroactive, he explains, ongoing research is threatened. "Research with almost all existing cell lines will not be fundable, leaving almost no federal funds for research using cells created ethically since 2001. This will mean a loss of much of the research benefit of the last eight years, even though that research was independently reviewed and determined to be ethical under federal standards," says Taylor. "It is vitally important that scientists are aware of this problem and that the situation is resolved as quickly as possible." Ronald McKay, director of the NIH Stem Cell Unit, agrees and points out that, as proposed, the current draft guidelines may not even allow for continued research on the 21 ES cell lines approved by President Bush in 2001. "It is important to recognize that continued access to the ES cells themselves is important for medical research," says McKay. "It is common to use the economic metaphor of the "gold standard" when discussing the value of human ES cells. But unlike gold, stem cells will not retain value if they are locked in a bank and we cannot analyze their secrets. Continued access to these cells will ensure no delay in understanding the links between human genetics and disease," he adds. The slow pace of commenting is symptomatic of a broader tendency within the scientific community. "Despite federal encouragement and the ease of posting a comment, scientists do not seem to be participating unless the proposals directly impact their research," outlines science writer Amy Maxman in an Analysis piece to be published by Cell Press in the journal Cell on the same day. The article explains how scientists can offer their views as part of the consultation on items listed at the Federal Register, such as by providing comments on the draft human ES cell guidelines currently under consideration, to ensure that federal agencies receive a balanced perspective of public opinion. Researchers from all scientific disciplines and interested members of the general public can comment on the proposed guidelines at http://nihoerextra.nih.gov/stem_cells/add.htm until 11 p.m. EST on May 26. The reseacher is Patrick Taylor, of Children"s Hospital Boston, Harvard Medical School, in Boston, MA. Cathleen Genova Cell Press


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):